Heart Failure

New findings from the THEMIS trial show patients with stable coronary artery disease and type 2 diabetes mellitus face major bleeding risks from the combination regimen.

Results of the DAPA-HF study — presented at the ESC Congress 2019, reveal use of dapagliflozin reduce hospitalizations from heart failure and deaths from cardiovascular causes in patients with heart failure with reduced ejection fraction.

Results of the PARAGON HF study, which were presented at ESC Congress 2019, reveal no significant benefit of sacubitril-valsartan compared to valsartan for heart failure with preserved ejection fraction in more than 4,500 patients.

An updated list of guidelines recommends using catheter ablation to treat supraventricular tachycardia.

The SGLT-2 inhibitor is seeking an additional indication for primary renal outcome prevention in patients with or without type 2 diabetes.

A primary investigator-led discussion will tap into how invasive procedures have become more embraced in US cardiology.

Results of the PolyIran study, which examined more than 6000 patients, found that use of a polypill reduced the risk of major cardiovascular events.

A recent analysis of the Asian Sudden Cardiac Death in Heart Failure registry found that type 2 diabetes mellitus was associated with structural changes of the heart and poorer quality of life.

Analysis of the Framingham Heart Study found that while quitting smoking lowers a person's CVD risk, that risk may not return to normal for up to 25 years.

The new device will treat patients who are not suited for other commonly used treatment options for advanced heart failure.

The committee meeting, tentatively scheduled for November 14, will have to precede the sNDA PDUFA action date set to review the drug's potential indication for reducing residual cardiovascular risks in patients with elevated triglycerides.

Just 2 weeks of therapy could help attenuated autonomic function for geriatric adults.

From vaping to air pollution, Deepak Bhatt, MD, shares his thoughts on the greatest threats to cardiovascular health.

A recent study of more than 12 million people from 10 countries found that the risk of heart failure associated with diabetes was greater in women than in men. 



A new study links high levels of high‐sensitivity cardiac troponin T and N‐terminal pro‐B‐type natriuretic peptide to an increase in fall risk for geriatric adults.

A recent analysis of the IMPROVE-IT results found that simvastatin-ezetimibe was associated with greater reductions in LDL-C and lower rates of MI, stroke and CVD than simvastatin monotherapy.

Why a revised recertification strategy would be beneficial for practicing internists and cardiologists.

Over time, clinicians have come to understand the most optimal use of the limited technological resources they have.

How the institution has become involved in regional health education efforts, and national efforts to establish proper care protocol.

Why limited educational resources and a diverse population has made the region an area burdened by heart disease.

Eli Lilly Co. and Boehringer Ingelheim Pharmaceuticals Inc. announced that empagliflozin (Jardiance) has received a Fast Track designation from the FDA.

A recent study found that an additional 2 hours per day of TV viewing time is linked to a 50% increase in a person's risk of cardiovascular events and death.

Recent analysis of 3 trials found that CERT2 showed comparable and synergistic predictive performance when compared with previously published CVD risk models.

Survey of 3000 found that more than half of all respondents wish they knew more about heart failure but just 1 in 5 were likely to speak with their doctor out of fear of diagnosis or cost.

A recent study from investigators at Michigan State University found that vitamin D supplementation was not associated with reduced risk of major cardiovascular events.